UBS Group
GNCA

UBS Group’s Genocea Biosciences, Inc. GNCA Stock Holding History

UBS Group’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,129
Closed -$1K – 11618
2021
Q4 		$1K Buy
+1,129
New +$1.68K ﹤0.01% 10200
2021
Q3 		– Sell
-3,834
Closed -$9K – 10823
2021
Q2 		$9K Buy
+3,834
New +$9.24K ﹤0.01% 8212
2020
Q4 		– Sell
-18,566
Closed -$43K – 9193
2020
Q3 		$43K Buy
+18,566
New +$48.7K ﹤0.01% 5769
2020
Q2 		– Sell
-245
Closed – – 8763
2020
Q1 		$0 Buy
+245
New +$495 ﹤0.01% 8880
2019
Q4 		– Sell
-2,954
Closed -$9K – 8799
2019
Q3 		$9K Sell
2,954
-1,724
-37% -$5.89K ﹤0.01% 7254
2019
Q2 		$19K Buy
4,678
+1,577
+51% +$8.23K ﹤0.01% 6673
2019
Q1 		$15K Sell
3,101
-238
-7% -$1.18K ﹤0.01% 6572
2018
Q4 		$8K Buy
3,339
+2,587
+344% +$12.9K ﹤0.01% 7387
2018
Q3 		$5K Buy
752
+595
+379% +$3.14K ﹤0.01% 7535
2018
Q2 		$1K Buy
+157
New +$1.17K ﹤0.01% 7897
2018
Q1 		– Sell
-803
Closed -$7K – 8408
2017
Q4 		$7K Buy
803
+93
+13% +$935 ﹤0.01% 7268
2017
Q3 		$8K Buy
710
+437
+160% +$16.6K ﹤0.01% 7034
2017
Q2 		$11K Sell
273
-407
-60% -$19.6K ﹤0.01% 6744
2017
Q1 		$33K Buy
680
+32
+5% +$1.25K ﹤0.01% 5801
2016
Q4 		$21K Sell
648
-60
-8% -$1.98K ﹤0.01% 6495
2016
Q3 		$29K Buy
708
+483
+215% +$18.9K ﹤0.01% 5983
2016
Q2 		$7K Sell
225
-46
-17% -$1.69K ﹤0.01% 7003
2016
Q1 		$17K Buy
271
+46
+20% +$1.46K ﹤0.01% 6334
2015
Q4 		$9K Sell
225
-194
-46% -$9.24K ﹤0.01% 7385
2015
Q3 		$23K Buy
419
+31
+8% +$3.07K ﹤0.01% 6591
2015
Q2 		$43K Buy
+388
New +$36K ﹤0.01% 6135
2015
Q1 		– Sell
-146
Closed -$8K – 9701
2014
Q4 		$8K Buy
+146
New +$9.97K ﹤0.01% 8644

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

UBS Group's GNCA Position: Q1 2022 in Review

UBS Group sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2022, closing a stake of 1,129 shares — an estimated $1K sold.

UBS Group first reported a position in GNCA in Q4 2014 and held it in 22 quarters. The position peaked at $43K in Q3 2020. 40 funds tracked by Wall St. Rank hold GNCA as of Q1 2022.

  • UBS Group reported no remaining Genocea Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
  • UBS Group sold 1,129 Genocea Biosciences, Inc. shares in Q1 2022, an estimated $1K.
  • UBS Group first reported a position in Genocea Biosciences, Inc. in Q4 2014 and held it in 22 quarters.
  • UBS Group's Genocea Biosciences, Inc. position peaked at $43K in Q3 2020.
  • 40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2022.

Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.